Key result
Proton-pump inhibitor use was independently associated with a lower risk of gastroduodenal ulcers or erosions in asymptomatic patients taking low-dose aspirin.
Why the study?
Does proton-pump inhibitor use reduce the prevalence of gastroduodenal ulcers or erosions in asymptomatic patients taking low-dose aspirin?
Observational (n=150)
Does proton-pump inhibitor use reduce the prevalence of gastroduodenal ulcers or erosions in asymptomatic patients taking low-dose aspirin?
Proton-pump inhibitor use is independently associated with a reduced risk of asymptomatic gastroduodenal ulcers and erosions in patients taking low-dose aspirin.
Answers are grounded in this paper and cite their sources.
PPI use was associated with fewer asymptomatic ulcers in low-dose aspirin patients; hypothesis-generating and should not yet change practice.
BACKGROUND: Although it is well known that aspirin causes gastroduodenal mucosal injury and that aspirin-induced gastroduodenal mucosal injury is often asymptomatic, the prevalence and independent factors for gastroduodenal mucosal injury have not been clarified in asymptomatic patients taking low-dose aspirin and gastroprotective agents. AIM: To clarify the prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents. DESIGN: Prospective observational study. METHODS: We performed endoscopy in 150 asymptomatic patients taking low-dose aspirin and gastroprotective agents for at least 3 months. RESULTS: Gastroduodenal ulcers/erosions were observed in 37.3% [ulcers (4.0%); erosions (34.0%)]. Univariate logistic regression analyses showed that proton-pump inhibitor (PPI) use was negatively associated with gastroduodenal ulcers/erosions [odds ratio (OR) 0.35, 95% confidence interval (95% CI) 0.17-0.75, P=0.007]. A multivariate logistic regression analysis selected PPI use as the only independent factor for gastroduodenal ulcers/erosions (OR 0.35, 95% CI 0.14-0.86, P=0.02). None of the 53 patients with PPI use had any gastroduodenal ulcers, and 11 with standard-dose PPI use tended to have a lower prevalence of gastroduodenal erosions than 42 with low-dose PPI use (0% vs. 28.6%, P=0.052). CONCLUSION: Gastroduodenal ulcers/erosions were observed in about one-third of asymptomatic patients taking low-dose aspirin and gastroprotective agents, and PPI use was a negative independent factor for gastroduodenal ulcers/erosions in those patients. In addition, standard-dose PPI therapy might be more effective in the prevention of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy.
No takes yet. Share an insight, caveat, or question.
Tamura et al. (2010) conducted an observational in Asymptomatic patients taking low-dose aspirin and gastroprotective agents (n=150). Proton-pump inhibitor (PPI) use vs. Non-PPI gastroprotective agents was evaluated on Gastroduodenal ulcers/erosions (OR 0.35, 95% CI 0.14-0.86, p=0.02). Proton-pump inhibitor use was independently associated with a lower risk of gastroduodenal ulcers or erosions in asymptomatic patients taking low-dose aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: